进行性家族性肝内胆汁淤积症
Progressive familial intrahepatic cholestasis
定义 英文原文(暂无中文)
Progressive familial intrahepatic cholestasis (PFIC) refers to a heterogeneous group of autosomal recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin.
别名
PFIC
基本事实
- 遗传方式
- 常染色体隐性
- 发病年龄
- 青少年期、儿童期、婴儿期、新生儿期
相关基因 7来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| ABCB11 | ATP binding cassette subfamily B member 11 | ORPHA:79304 |
| ABCB4 | ATP binding cassette subfamily B member 4 | ORPHA:79305 |
| ATP8B1 | ATPase phospholipid transporting 8B1 | ORPHA:79306 |
| MYO5B | myosin VB | ORPHA:79306 |
| NR1H4 | nuclear receptor subfamily 1 group H member 4 | ORPHA:480476 |
| TJP2 | tight junction protein 2 | ORPHA:480483 |
| UTP4 | UTP4 small subunit processome component | ORPHA:168583 |
临床表型 14
极常见 99–80%9
- 凝血异常 HP:0001928
- 胆汁淤积 HP:0001396
- 认知功能损害 HP:0100543
- 发育迟滞 HP:0001508
- 肝脏肿大 HP:0002240
- 黄疸 HP:0000952
- 吸收不良 HP:0002024
- 身材矮小 HP:0004322
- 脾肿大 HP:0001744
常见 79–30%4
- 血小板异常 HP:0001872
- 骨成熟延迟 HP:0002750
- 低钙血症 HP:0002901
- 骨密度降低 HP:0004349
偶见 29–5%1
- 肿瘤 HP:0002664
近两年的全球研究 497L2
2024/08 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-08Molecular Mechanisms of Progressive Familial Intrahepatic Cholestasis
- 2026-08Contrasting Impacts of Two ABCB11 Variants Affecting the Same Residue in Progressive Familial Intrahepatic Cholestasis Type 2
- 2026-08Hepatic iron accumulation is reduced in the cholestatic Mdr2-/- mouse
- 2026-07From one-size-fits-all to on-demand: personalized crispr gene editing for rare genetic liver diseases
- 2026-07综述Parvovirus B19 infection as a trigger of acute cholestasis in heterozygous genetic BSEP deficiency: a case report and review of the literature of acute parvovirus B19-related hepatitis
- 2026-07Genotype-Phenotype Correlations of Monoallelic PFIC Variants in Pediatric Liver Disease: A Multicenter Retrospective Cohort Study
- 2026-07New percentiles of gamma-glutamyl transferase serum levels in infants and the role of breastfeeding
- 2026-07病例报告Compensated Cirrhosis in a 40-Year-Old Woman With Progressive Familial Intrahepatic Cholestasis Type 3
- 2026-07Natural history and the outcome of complications of children with progressive familial intrahepatic cholestasis in a resource-limited setting: A cohort study
- 2026-07综述Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies
- 2026-07Beyond citrulline: The diagnostic accuracy of amino acid ratios in neonatal intrahepatic cholestasis caused by citrin deficiency
- 2026-07系统综述综述Diagnostic challenges in progressive familial intrahepatic cholestasis type 3 (PFIC3) misdiagnosed as Wilson's disease: A systematic review
- 2026-06病例报告开放获取Delayed Diagnosis of Low Phospholipid-Associated Cholelithiasis Syndrome, Consideration of DHCR7 Mutations
- 2026-06Rare Variants in PFIC-Related Genes Among Adults With Intrahepatic Cholestasis
- 2026-06病例报告开放获取Recurrent Intrahepatic Hepatolithiasis Associated With Low-Phospholipid-Associated Cholelithiasis Syndrome: An Underdiagnosed Pathology
- 2026-06病例报告Progressive Familial Intrahepatic Cholestasis Type 7 in a 4 Month Old Female, Japanese Infant: A Case Report
- 2026-06开放获取A Hematologic Masquerader: Progressive Familial Intrahepatic Cholestasis Type 3 Presenting as Anemia, Hepatosplenomegaly, and Recurrent Bleeding in a Child
- 2026-06病例报告开放获取Ileal Bile Acid Transporter Inhibitors for Symptomatic Cholestasis due to Vanishing Bile Duct Syndrome in Adults
- 2026-06病例报告Resolving a Complex Neonatal Phenotype by Rapid Trio Whole-Genome Sequencing: A De Novo 11q14.3-q22.3 Deletion and a Splicing-Altering Synonymous ANK1 Variant
- 2026-06开放获取GGT-Normal Cholestasis in an Older Child: A Suspected Case of Benign Recurrent Intrahepatic Cholestasis From Syria
境外已获批用于本病的药物 3L2
欧盟 1 项、美国 2 项。同一药物在两地各批一次的,会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。
药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。
已获孤儿药资格、尚未获批的在研药物(4 项)
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励,不代表这个药已被证明有效,也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Livmarli欧盟2014-01-16(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxi…Treatment of progressive familial intrahepatic cholestasis官方记录
- 3alpha,6beta,7beta,12alpha-tetrahydroxy-5beta-cholan-24-oic acid美国2020-10-22treatment of progressive familial intrahepatic cholestasis官方记录
- modified human ATP binding cassette subfamily B member 11 (ABCB11) mes美国2024-07-29treatment of progressive familial intrahepatic cholestasis官方记录
- modified human ATP binding cassette subfamily B member 4 (ABCB4) mRNA 美国2024-11-18treatment of progressive familial intrahepatic cholestasis官方记录
数据来自欧洲药品管理局(EMA)的药品与孤儿药资格公开导出表,以及美国 FDA 孤儿药资格数据库。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
在中国开展的临床试验 1L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
登记为可入组 1
- 招募中NCT07588880A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China中国研究中心 5 个:Beijing、Hunan、Nanjing、Shanghai、Xiamen
中国境外的在招试验 12L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
CT.gov 报告命中 12 项,此处取回并展示最近的 11 项。
- 招募中NCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in Canada加拿大
- 招募中NCT06506734Dental Dyschromia and Quality of Life in Early Prolonged Hyperbilirubinemia法国
- 招募中NCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)日本
- 招募中NCT07317193DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE意大利
- 招募中NCT07185919A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea韩国
- 招募中NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)比利时、法国、德国、希腊、意大利、荷兰、葡萄牙、西班牙
- 招募中NCT06777914Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers意大利
- 招募中NCT06781242Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis意大利
- 招募中NCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)美国
- 招募中NCT06778174Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC)荷兰
- 招募中NCT01793168Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford澳大利亚、美国
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)